Zofran Lawsuit Plaintiffs See Allegations Supported Through Study Results Connecting Drug To Possible Twofold Increase In Cleft Palate Development

March 31, 2016 – – ZofranLegal.com reports on several study resutls which appear to connect fetal exposure to the anti-nausea drug Zofran to increased risk for the development of several serious birth defects. The drug, which is manufactured by GlaxoSmithKline, has recently become the subject of great public controversy. Zofran has also been the subject of hundreds of lawsuits filed by plaintiffs who are upset over a highly controversial marketing decision that GSK made when the corporation chose to advertise the drug “off-label” (for a use which was approved by the FDA), to expectant mothers, without testing the drug for their safety or the safety of their unborn children.

The United States Food and Drug Administration (FDA) approved Zofran as a drug used to treat patients suffering from nausea and vomiting episodes following chemotherapy, radiation, or anesthesia. After the drug gained this approval, however, GSK reportedly began to market the drug as a safe and effective treatment for morning sickness to both Ob/Gyn offices nation-wide and the general public.

Since this time, Zofran has been widely prescribed “off-label” to the extent that reports indicate that the drug was prescribed to an estimated 1 million women within one year. Today, GSK is facing an increasing number of lawsuits filed by parents across the nation who similarly allege that their children were born with a range of serious and even fatal birth defects because exposure to Zofran through their mothers while developing in the womb. Most commonly, the defects allegedly caused by the drug are noted as: cleft lip and palate, transposition of the greater vessels, kidney defects, respiratory distress syndrome, clubfoot, tetralogy of fallot, atrial septal defect and ventricular septal defect.

There are multiple studies which were conducted that appear to lend support to Zofran lawsuit plaintiffs’ arguments. A study conducted in 2012 appeared to highlight a possible twofold increase in the possibility of cleft palate development among babies who were exposed to Zofran while growing in utero. Another study from 2014 appeared to show that Zofran exposure could cause a 30% overall increased risk for the development of congenital malformations in unborn babies.

Zofran lawsuits were transferred to a single Court and consolidated by the U.S. Judicial Panel on Multidistrict Litigation, forming MDL number 2657. These lawsuits are now being overseen in Eastern Massachusetts by Judge F. Dennis Saylor IV. As the plaintiffs involved anxiously await trial dates, the attorneys of Monheit Law are working to help others who have taken Zofran while pregnant and who have subsequently given birth to children with defects. These mothers, children, and families may be entitled to significant compensation attained through legal action. In order to assist those wishing to look further into legal action, the attorneys of Monheit Law are also currently offering free legal consultations for qualified parties.

To request further information on Zofran birth defect lawsuits ,or to ask questions, please contact Michael Monheit, Esq., of Monheit Law by calling (877) 620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60009008